Infectious Diseases
Volume 51, 2019 - Issue 11-12
Original Articles
Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection
Aylin YilmazDepartment of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; ;Department of Infectious Diseases, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden; Correspondence[email protected]
http://orcid.org/0000-0001-7612-5828View further author information
http://orcid.org/0000-0001-7612-5828View further author information, Åsa MellgrenClinic of Infectious Diseases, Södra Älvsborg Hospital, Borås, Sweden; http://orcid.org/0000-0002-1202-3504View further author information
http://orcid.org/0000-0002-1202-3504View further author information, Dietmar FuchsDivision of Biological Chemistry, Biocenter, Innsbruck Medical University, Innsbruck, Austria; http://orcid.org/0000-0003-1627-9563View further author information
http://orcid.org/0000-0003-1627-9563View further author information, Staffan NilssonMathematical Sciences, Chalmers University of Technology, Gothenburg, Sweden; http://orcid.org/0000-0003-4748-0446View further author information
http://orcid.org/0000-0003-4748-0446View further author information, Kaj BlennowInstitute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden; ;Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Molndal, Sweden; http://orcid.org/0000-0002-1890-4193View further author information
http://orcid.org/0000-0002-1890-4193View further author information, Henrik ZetterbergInstitute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden; ;Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Molndal, Sweden; ;Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK; ;UK Dementia Research Institute at UCL, London, UKhttp://orcid.org/0000-0003-3930-4354View further author information
http://orcid.org/0000-0003-3930-4354View further author information & Magnus GisslénDepartment of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; ;Department of Infectious Diseases, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden; http://orcid.org/0000-0002-2357-1020View further author information
http://orcid.org/0000-0002-2357-1020View further author information show all